Multicentric malignant Schwannoma in a crossbred cow is described. Multiple and solitary nodules of varying sizes were seen to be distributed throughout the body of the animal, mainly along the peripheral nerves supplying the muscles of the thoracic and abdominal regions and the skin. Multiple nodules were also observed in the hilus of the liver. The mediastinal lymph nodes were replaced by a large solitary tumorous mass. Multiple neoplastic linear cords with small nodules were observed on the pericardium. Histologically, the nodules showed mainly densely packed, spindle-shaped cells arranged in short interwoven bundles and whorls (Antoni type A pattern). Stellate, spindle-shaped and round or oval tumour cells proliferated haphazardly within the loose texture of a collagenous matrix (Antoni type B pattern). Immunohistochemically, in both Antoni type A and type B areas, neoplastic cells reacted with antibodies against S-100 protein. Based on the metastasis of the tumour to the lymph nodes and on histology, the neoplasm was diagnosed as a multicentric malignant Schwannoma.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jcpa.2005.10.006 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Nationwide multi-centric prospective study for the identification of biomarkers to predict the treatment responses of nivolumab through comprehensive analyses of pretreatment plasma exosome mRNAs from head and neck cancer patients (BIONEXT study).
Front Immunol
January 2025
Department of Head and Neck Surgery, National Hospital Organization Kyushu Cancer Center, Fukuoka, Fukuoka, Japan.
Background: Nivolumab paved a new way in the treatment of patients with recurrent or metastatic (RM) head and neck squamous cell carcinoma (RM-HNSCC). However, the limited rates of long-term survivors (< 20%) demand a robust prognostic biomarker. This nationwide multi-centric prospective study aimed to identify a plasma exosome (PEX) mRNA signature, which serves as a companion diagnostic of nivolumab and provides a biological clue to develop effective therapies for a majority of non-survivors.
View Article and Find Full Text PDFFluid intake and recurrence and progression risk of patients with non-muscle-invasive bladder cancer.
BJU Int
January 2025
IQ Health science department, Radboud University Medical Center, Nijmegen, The Netherlands.
Objectives: To evaluate the association of pre- and post-diagnosis fluid intake with non-muscle-invasive bladder cancer (NMIBC) recurrence and progression risk.
Patients And Methods: Data were used from the multicentre prospective cohort study UroLife. Participants reported pre-diagnosis fluid intake at 6 weeks (food frequency questionnaire [FFQ]) (n = 1322) and post-diagnosis fluid intake at 3 and 15 months (FFQ and 4-day 24-h fluid diaries) (n = 1275) after diagnosis.
Safety and efficacy of satralizumab in patients with generalised myasthenia gravis (LUMINESCE): a randomised, double-blind, multicentre, placebo-controlled phase 3 trial.
Lancet Neurol
February 2025
Department of Neurology, International University of Health and Welfare, Narita, Japan.
Background: Evidence from preclinical studies suggests that IL-6 signalling has the potential to modulate immunopathogenic mechanisms upstream of autoantibody effector mechanisms in patients with generalised myasthenia gravis. We aimed to assess the safety and efficacy of satralizumab, a humanised monoclonal antibody targeting the IL-6 receptor, in patients with generalised myasthenia gravis.
Methods: LUMINESCE was a randomised, double-blind, placebo-controlled, multicentre, phase 3 study at 105 sites, including hospitals and clinics, globally.
Exosomal Liquid Biopsy in Prostate Cancer: A Systematic Review of Biomarkers for Diagnosis, Prognosis, and Treatment Response.
Int J Mol Sci
January 2025
Department of Medical Oncology, Medway NHS Foundation Trust, Gillingham ME7 5NY, UK.
Prostate cancer, a leading cause of cancer-related mortality among men, often presents challenges in accurate diagnosis and effective monitoring. This systematic review explores the potential of exosomal biomolecules as noninvasive biomarkers for the diagnosis, prognosis, and treatment response of prostate cancer. A thorough systematic literature search through online public databases (Medline via PubMed, Scopus, and Web of science) using structured search terms and screening using predefined eligibility criteria resulted in 137 studies that we analyzed in this systematic review.
View Article and Find Full Text PDFThe Rare Entity of Basaloid Thymic Carcinoma: A Multicentric Retrospective Analysis from the Italian Collaborative Group for ThYmic MalignanciEs (TYME).
Cancers (Basel)
January 2025
Medical Oncology Division, Humanitas Gavazzeni, 24125 Bergamo, Italy.
Background: thymic basaloid carcinoma (BTC) is an extremely rare tumor, and very little data are available on BTC's biology, clinical behavior, drug sensitivity, and patient outcomes.
Methods: We performed a retrospective observational study on patients diagnosed with BTC in 11 referral centers of TYME. All BTC diagnoses were reviewed by the referring pathologist.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!